The company has been granted one product patent from Australia corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases, it said in a BSE filing.
"The audit of our API Cuernavaca plant in Mexico by the USFDA has been completed with zero observations," Dr Reddy's Laboratories (DRL) said in a BSE filing.
This is against a net profit of Rs 74.1 crore in the year-ago period, Zensar said in a statement.
The decision to this effect was taken in the Annual General Meeting held today in Mumbai, the bank said in a filing to BSE.
The company's revenues increased by 5.7 per cent to Rs 708.9 crore in the said quarter from Rs 670.7 crore in the April-June period last year.
The company, which publishes Dainik Bhaskar newspaper, had posted a net profit of Rs 103.95 crore during the same quarter of previous fiscal, DB Corp informed BSE.
The company had posted a net profit of Rs 126.50 crore in the year-ago period.
The firm posted a 16.6 percent year on year (YoY) fall in its net profits for the June quarter at Rs 121.3 crore against Rs 145.6 crore.
In a regulatory filing, Eros said Eros Worldwide FZ LLC, which had 43.51 per cent stake earlier, sold 33.86 lakh shares in the open market between July 7-19.
"With reference to the earlier intimation of the meeting of the board of directors to be held on July 24, 2017... the board will also consider a proposal for buyback of equity shares of the company at the said meeting," Justdial said in a BSE filing today.
Natco Pharma announces successful EIR from the US Food and Drug Administration (USFDA) for the inspection conducted at its drug manufacturing facility in Kothur village in Mahabubnagar district during January 16–24, 2017, the company said in a BSE filing today.
Kumar is a veteran of the Delhi-based debt-laden group that has interests in power, cement, roads, hotels and engineering, procurement and construction.
SMTB had purchased the stake in Reliance Capital (RCap) when the latter had applied for a banking licence. The Japanese major was planning to be a strategic partner in the proposed banking venture.
The company had registered net profit of Rs 37.74 crore in the same period a year ago.
Total income rose 39 per cent to Rs 3,165 crore for the June quarter as against Rs 2,282 crore a year ago, the company said in a regulatory filing.
"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Sevelamer Carbonate tablets 800 mg," Aurobindo Pharma said in a BSE filing today.
"Zydus Cadila has commercially launched its mesalamine delayed release tablets in the US market. Zydus was the first to file an Abbreviated New Drug Application (ANDA) for the generic version of Lialda," the company said in a BSE filing today.
In a BSE filing, Glenmark Pharmaceuticals said, "it has entered into a development, license, manufacture and commercial supply agreement with Cyndea Pharma S L, granting exclusive rights to use their technology for developing generic, soft-gelatin capsule formulations of certain pharmaceutical products".
It's consolidated income from operations was up 8.6 per cent to Rs 407.30 crore for the quarter-ended June 2017 compared to Rs 374.97 crore in the same period year-ago.
The company had reported a net profit of Rs 90.17 crore in the same quarter of the previous year.
BSE would shift as many as 28 stocks, including Shriram Asset Management Company and Sahara One Media & Entertainment, to the trade-for-trade segment represented by 'T', 'XT' or 'ST' groups.
The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Olmesartan Medoxomil and Amlodipine tablets, Alembic Pharmaceuticals said in a BSE filing.
Underlying volume growth was flat, which was on expected lines due to disruption ahead of GST rollout on July 1.
The public sector insurer, which had 9.85 per cent stake earlier, brought down its shareholding in the company to 7.70 per cent by selling shares between July 20, 2016, and July 4, 2017, Tata Global Beverages (TGBL) said in a filing to BSE.
The company had posted a net profit of Rs 39.25 crore in the April-June quarter of the previous fiscal.